Gentian Diagnostics AS's total inventories for the quarter that ended in Jun. 2026 was €4.85 Mil. Gentian Diagnostics AS's average total inventories from the quarter that ended in Mar. 2026 to the quarter that ended in Jun. 2026 was €4.90 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Gentian Diagnostics AS's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was €0.58.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Gentian Diagnostics AS's Days Inventory for the
three
months ended in Jun. 2026 was 222.05.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Gentian Diagnostics AS's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.41.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Gentian Diagnostics AS's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 1.09.
Gentian Diagnostics AS (FRA:6FK) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Gentian Diagnostics AS's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Gentian Diagnostics AS's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Gentian Diagnostics AS Total Inventories Related Terms
Gentian Diagnostics AS Total Inventories Historical Data
* Premium members only.
The historical data trend for Gentian Diagnostics AS's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Gentian Diagnostics AS (FRA:6FK) has a Total Inventories of €4.85 Mil as of Jun. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Gentian Diagnostics AS and its competitors.
Is Gentian Diagnostics AS's Total Inventories too high?
Gentian Diagnostics AS's current Total Inventories is €4.85 Mil. Overall, Gentian Diagnostics AS has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Total Inventories compare to ABT and SYK?
Gentian Diagnostics AS's Total Inventories of €4.85 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current Total Inventories is €4.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (FRA:6FK) is currently considered Significantly Undervalued. The stock's GF Value™ is €5.19, compared to a current price of €3.47 — trading 33.1% below its estimated fair value. The current Total Inventories is €4.85 Mil. Gentian Diagnostics AS's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Gentian Diagnostics AS (FRA:6FK), the current Total Inventories is €4.85 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (FRA:6FK) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of €3.47 is trading 33.1% below its estimated GF Value™ of €5.19.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for FRA:6FK:
Total Inventories: €4.85 Mil
GF Value™: €5.19 vs. price of €3.47 (33.1% below fair value)
No single metric tells the full story. See the FRA:6FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
73GF Score
Get the complete analysis for FRA:6FK
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FK has been successfully added to your 
